Eli Lilly and Company (NYSE:LLY) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 175,743 shares of the company’s stock after selling 4,558 shares during the quarter. Retirement Systems of Alabama’s holdings in Eli Lilly and Company were worth $102,444,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Meridian Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 5.6% during the 4th quarter. Meridian Wealth Partners LLC now owns 607 shares of the company’s stock worth $354,000 after acquiring an additional 32 shares in the last quarter. Magnus Financial Group LLC lifted its holdings in shares of Eli Lilly and Company by 3.1% in the 4th quarter. Magnus Financial Group LLC now owns 5,418 shares of the company’s stock valued at $3,158,000 after purchasing an additional 163 shares during the last quarter. Convergence Investment Partners LLC lifted its holdings in shares of Eli Lilly and Company by 9.5% in the 4th quarter. Convergence Investment Partners LLC now owns 1,554 shares of the company’s stock valued at $906,000 after purchasing an additional 135 shares during the last quarter. Little House Capital LLC lifted its holdings in shares of Eli Lilly and Company by 85.3% in the 4th quarter. Little House Capital LLC now owns 2,515 shares of the company’s stock valued at $1,466,000 after purchasing an additional 1,158 shares during the last quarter. Finally, Kapstone Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $292,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Morgan Stanley boosted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Truist Financial reissued a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, Citigroup upped their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $8.64 during trading hours on Friday, reaching $733.51. 2,009,249 shares of the company’s stock were exchanged, compared to its average volume of 2,265,427. The company has a market cap of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company’s 50 day moving average is $761.79 and its two-hundred day moving average is $666.67. Eli Lilly and Company has a 1 year low of $380.77 and a 1 year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.09 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.